Recovery Time in Thai Patients With Upper or Lower Respiratory Tract Infections Treated With Klacid MR

Abbott

Status: Completed

Conditions: Respiratory Tract Infection

Treatments: Drug: Clarithromycin (Klacid® MR)

Study type: Observational

Funder types: Industry

Identifiers

NCT01076153

P08-331

Details and patient eligibility

About

The investigators hypothesize that Klacid modified release (MR) shortens symptom recovery time in Thai patients with upper or lower respiratory tract infections.

Enrollment: 760 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with upper or lower respiratory tract infection.
• Patient is male or female ≥ 18 years of age.

Exclusion criteria

• Known hypersensitivity to or previously intolerant of macrolides.

• Illness severe enough to warrant hospitalization or parenteral therapy.

• Concomitant use of any of the following medications:

  • Drugs metabolized by CYP3A isozyme: alprazolam, astemizole, carbamazepine, cilostazol, cisapride, cyclosporin, disopyramide, ergot alkaloids, lovastatin, methylprednisolone, midazolam, omeprazole, oral anticoagulants (e.g. warfarin), pimozide, quinidine, rifabutin, sildenafil, simvastatin, tacrolimus, terfenadine, triazolam and vinblastine.
  • Drugs metabolized by other isozymes within CYP450 system: phenytoin, theophylline and valproate.
  • Colchicine
  • Digoxin
  • Some antiretrovirals: zidovudine and ritonavir.

• Severe immunodeficiency and chronic disease conditions.

• Renal or hepatic impairment.

Trial design

760 participants in 1 patient group

Patients with respiratory tract infection

Description:

Thai patients with upper or lower respiratory tract infections on Klacid MR.

Treatment:

Drug: Clarithromycin (Klacid® MR)